Metraipolis › archive › dc_bc04e9e006f4

The impact of caplacizumab in the treatment of immune thrombotic thrombocytopenic purpura. A retrospective monocentric cohort study — Europe PMC PMID:42222145

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42222145
DOI
10.3389/fphar.2026.1761391
License (as archived)
solo-consultazione
Archived
2026-11-02T06:42:45.726Z
SHA-256 of the archived text
840c557759572ed95712e33cf59d0caa465ba52e446d8526b17c9eb305b3eadb
Stable URL of this page
https://metraipolis.com/documento/dc_bc04e9e006f4

How to cite

The impact of caplacizumab in the treatment of immune thrombotic thrombocytopenic purpura. A retrospective monocentric cohort study — Europe PMC PMID:42222145 — Europe PMC (en), https://europepmc.org/article/MED/42222145 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_bc04e9e006f4 (Metraipolis archive dc_bc04e9e006f4, sha256 840c557759572ed95712e33cf59d0caa465ba52e446d8526b17c9eb305b3eadb)
BibTeX
@misc{dcbc04e9e006f4,
  title = {The impact of caplacizumab in the treatment of immune thrombotic thrombocytopenic purpura. A retrospective monocentric cohort study — Europe PMC PMID:42222145},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42222145},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_bc04e9e006f4; sha256 840c557759572ed95712e33cf59d0caa465ba52e446d8526b17c9eb305b3eadb},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42222145. Agents can read the archived copy with the MCP tool read_document.